Loading...
•
Dec 31, 2023
Pulse Biosciences Q4 2023 Earnings Report
Announced business updates and financial results.
Key Takeaways
Pulse Biosciences reported a GAAP net loss of ($11.9) million for Q4 2023, compared to ($9.2) million for Q4 2022. Total GAAP costs and expenses were $12.5 million, up from $8.7 million in the prior year period. Cash and cash equivalents totaled $44.4 million as of December 31, 2023.
Received U.S. FDA 510(k) clearance for CellFX nsPFA Percutaneous Electrode for non-cardiac soft tissue ablation.
Completed enrollment in the first-in-human clinical trial for benign thyroid nodules.
Completed 60-Day post-procedure evaluations of initial patients treated in the CellFX nsPFA 360° Cardiac Catheter study.
Filed FDA 510(k) submission for CellFX nsPFA Cardiac Clamp in December 2023.
Forward Guidance
Pulse Biosciences plans to initiate a rights offering and has filed a preliminary registration statement with the SEC to establish a universal shelf to fund future operations.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...